News & Events

At Diazyme Laboratories, we take pride in offering innovative diagnostic solutions that empower healthcare professionals to make informed decisions. One such professional who has played a significant role in advancing diagnostic testing is Dr. Alan H.B. Wu, Ph.D. For nearly a decade, Dr. Wu has been a trusted and loyal customer, helping to shape the future of diagnostics by using Diazyme’s unique products.

In his recent testimonial, Dr. Wu, a leader in Kappa and Lambda Free Light Chain research, highlights how Diazyme’s Free Light Chain assays have filled important gaps in diagnostic testing. These assays, which Dr. Wu integrates into his laboratory workflows, have been instrumental in diagnosing and managing Multiple Myeloma. By measuring Kappa and Lambda Free Light Chains, Dr. Wu and his team can assess the progression of the disease, evaluate the effectiveness of treatments, and monitor for potential relapses. These insights are critical for determining the best management decisions for patients.

Dr. Wu also shares how Diazyme’s ADA (Adenosine Deaminase) assay has been pivotal in his work diagnosing Tuberculosis (TB) —a persistent global health challenge, especially in developing countries. Combining ADA testing with traditional methods like bacterial culture and molecular techniques, Dr. Wu can achieve more accurate and timely diagnoses. He emphasizes how ADA levels in body fluids are easier to measure compared to other approaches, streamlining the diagnostic process.

Diazyme is honored to work with forward-thinking customers like Dr. Alan Wu, whose research and clinical work are expanding the possibilities of diagnostics. His endorsement of our Free Light Chain and ADA assays underscores the real-world impact of these tests in improving patient outcomes.

We invite you to watch Dr. Wu’s full video testimony and explore how these powerful assays can enhance your diagnostic capabilities. For more information about Diazyme’s diagnostic solutions, please reach out to us at sales@diazyme.com.